Find, compare & contact
Itanapraced API Manufacturers & Suppliers

teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Itanapraced is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Itanapraced or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Itanapraced API 749269-83-8?

Description:
Here you will find a list of producers, manufacturers and distributors of Itanapraced. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Itanapraced 
Synonyms:
 
Cas Number:
749269-83-8 
DrugBank number:
DB16825 
Unique Ingredient Identifier:
C35RF1MWQZ

General Description:

Itanapraced is a chemical compound identified by the CAS number 749269-83-8. It is known for its distinct pharmacological properties and applications.

Categories:

Itanapraced is categorized under the following therapeutic classes: Acids, Acyclic, Amyloid Precursor Protein Secretases, antagonists & inhibitors, Benzene Derivatives, Biphenyl Compounds, Cycloparaffins, Enzyme Inhibitors, Gamma Secretase Inhibitors and Modulators, Propionates. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Itanapraced is a type of Enzyme Replacements/modifiers


Enzyme replacements/modifiers are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various enzyme-related disorders. Enzymes play a vital role in the normal functioning of the body by catalyzing specific biochemical reactions. However, in certain medical conditions, the body may lack or produce dysfunctional enzymes, leading to serious health complications.

Enzyme replacement therapy (ERT) involves administering exogenous enzymes to compensate for the enzyme deficiency in patients. These enzymes are typically derived from natural sources or produced using recombinant DNA technology. By introducing these enzymes into the body, they can effectively substitute the missing or defective enzymes, thereby restoring normal metabolic processes.

On the other hand, enzyme modifiers are API substances that regulate the activity of specific enzymes within the body. These modifiers can either enhance or inhibit the enzyme's function, depending on the therapeutic objective. By modulating enzyme activity, these APIs can restore the balance of enzymatic reactions, leading to improved physiological outcomes.

Enzyme replacements/modifiers have shown remarkable success in treating various genetic disorders, such as Gaucher disease, Fabry disease, and lysosomal storage disorders. Additionally, they have demonstrated potential in managing enzyme deficiencies associated with rare diseases and certain types of cancer.

The development and production of enzyme replacements/modifiers involve rigorous research, formulation optimization, and adherence to stringent quality control measures. Pharmaceutical companies invest substantial resources in developing these APIs to ensure their safety, efficacy, and compliance with regulatory standards.

Overall, enzyme replacements/modifiers represent a vital therapeutic category in modern medicine, offering hope and improved quality of life for patients with enzyme-related disorders.